ClinicalTrials.gg

Uterine Cervical Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,368 studies for Uterine Cervical Neoplasms across more than 10 countries. 678 are recruiting or about to start. 1,631 of them are mainly about Uterine Cervical Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 2,635 studies for Uterine Cervical Neoplasms. How that becomes 2,368 hereChecked on ClinicalTrials.gov Nov 16, 2026

This page counts the studies the registry files under Uterine Cervical Neoplasms, and those it files under no condition that list Uterine Cervical Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Its counts are asked again about once a week. How condition pages count

  1. 2,635Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −10List Uterine Cervical Neoplasms as a condition, but the registry did not file them under itMost often written as “Stage 0 Cervical Cancer” (2), “Cancer Cervix Uterus” (2), and “Cervical Cancer Screening” (2). The registry filed them under other conditions only, most often Uterine Cervical Dysplasia (9) and Papillomavirus Infections (2).
  3. −372Match it another way24 name it in the title, 4 in a keyword, and 344 by a synonym or other text the search reads.
  4. 2,253Counted here and found by its search1 of them list Uterine Cervical Neoplasms in their own words; the registry filed them under no condition.
  5. +115
    Counted here, but its search does not find themThe first 20 of 115.
  6. 2,368The count on this page

Status

Completed
978
Recruiting
474
Status unknown
320
Not yet recruiting
180
Active, not recruiting
167
Terminated
155

Phase

Phase 2
596
Phase 1
381
Phase 3
208
Phase 4
42
Early Phase 1
24

Where

United States
834
China
455
France
147
Canada
139
Italy
101
United Kingdom
92

Who develops what

Add Uterine Cervical Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 44 programs from 38 companies, 17 with this as their studies’ main aim; 9 with a live phase 3 study; 11 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine, Merck and Pfizer here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07216703 · Merck & Co., Inc · Phase 3 · live · background · “Carboplatin” · registered Oct 2025
  • NCT07168200 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Carboplatin Injection” · registered Sep 2025
  • NCT06859775 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Carboplatin injection” · registered Feb 2025
  • NCT06535607 · AstraZeneca · Phase 2 · live · background · “Carboplatin” · registered Jul 2024
  • NCT06241235 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2 · live · background · “Carboplatin” · registered Jan 2024
Eli Lilly and Company16% of its industry studies911 studies
PaclitaxelRecent, repeated
Evidence
  • NCT07418749 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel for Injection (Albumin bound)” · registered Feb 2026
  • NCT07216703 · Merck & Co., Inc · Phase 3 · live · background · “Paclitaxel” · registered Oct 2025
  • NCT07168200 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Paclitaxel Injection” · registered Sep 2025
  • NCT06535607 · AstraZeneca · Phase 2 · live · background · “Paclitaxel” · registered Jul 2024
  • NCT06241235 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2 · live · background · “Paclitaxel” · registered Jan 2024
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed810 studies
BevacizumabRecent, repeated
Evidence
  • NCT07497074 · Alphamab Oncology · Phase 2 · live · background · “Bevacizumab” · registered Mar 2026
  • NCT07216703 · Merck & Co., Inc · Phase 3 · live · background · “Bevacizumab” · registered Oct 2025
  • NCT07080216 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2 · live · background · “Bevacizumab” · registered Jul 2025
  • NCT07054567 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Bevacizumab” · registered Jun 2025
  • NCT06859775 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Bevacizumab injection” · registered Feb 2025
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others89 studies
CisplatinRecent, repeated
Evidence
  • NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “Cisplatin” · registered Aug 2026
  • NCT07216703 · Merck & Co., Inc · Phase 3 · live · background · “Cisplatin” · registered Oct 2025
  • NCT07168200 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Cisplatin Injection” · registered Sep 2025
  • NCT06859775 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Cisplatin injection” · registered Feb 2025
  • NCT06535607 · AstraZeneca · Phase 2 · live · background · “Cisplatin” · registered Jul 2024
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed710 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
  • NCT07054567 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Jun 2025
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2023
  • NCT05579366 · Genmab · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2022
  • NCT05081609 · Ascendis Pharma Oncology Division A/S · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2021
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)44 studies
GemcitabineRecent, repeated
Evidence
  • NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “Gemcitabine” · registered Aug 2026
  • NCT07797153 · Alphamab Oncology · Phase 3 · live · comparator · “Gemcitabine (GEM)” · registered Aug 2026
  • NCT07418749 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine Hydrochloride for Injection” · registered Feb 2026
  • NCT06459180 · Merck & Co., Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Jun 2024
  • NCT06241781 · Grit Biotechnology · Phase 2 · live · comparator · “Gemcitabine injection” · registered Jan 2024
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed45 studies
DocetaxelRecent, repeated
Evidence
  • NCT07797153 · Alphamab Oncology · Phase 3 · live · comparator · “Docetaxel” · registered Aug 2026
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Docetaxel (Taxotere)” · registered Oct 2022
  • NCT05383482 · Laekna Limited · Phase 2 · background · “Docetaxel” · registered Apr 2022
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Docetaxel” · registered Aug 2021
  • NCT04895709 · Bristol-Myers Squibb · Phase 2 · live · background · “Docetaxel” · registered May 2021
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized33 studies
FulvestrantRecent, repeated
Evidence
  • NCT07109726 · Terremoto Biosciences Inc. · Phase 2 · live · background · “Fulvestrant injection” · registered Jul 2025
  • NCT06993844 · Ensem Therapeutics · Phase 2 · live · background · “ETX-636 dose escalation in combination with fulvestrant” · registered May 2025
  • NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Fulvestrant” · registered Mar 2023
  • NCT04579380 · Pfizer · Phase 2 · live · background · “fulvestrant” · registered Oct 2020
AstraZeneca70% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 1 generic authorized33 studies
TopotecanRecent, repeated
Evidence
  • NCT07797153 · Alphamab Oncology · Phase 3 · live · comparator · “Topotecan” · registered Aug 2026
  • NCT07418749 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Topotecan Hydrochloride for Injection” · registered Feb 2026
  • NCT06459180 · Merck & Co., Inc · Phase 3 · live · comparator · “Topotecan” · registered Jun 2024
  • NCT04943627 · Agenus Inc. · Phase 3 · comparator · “Topotecan” · registered Jun 2021
  • NCT04697628 · Pfizer · Phase 3 · comparator · “topotecan” · registered Jan 2021
GlaxoSmithKline55% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 1 generic authorized33 studies
PemetrexedRecent, repeated
Evidence
  • NCT07797153 · Alphamab Oncology · Phase 3 · live · comparator · “Pemetrexed” · registered Aug 2026
  • NCT07418749 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Pemetrexed Disodium for Injection” · registered Feb 2026
  • NCT06459180 · Merck & Co., Inc · Phase 3 · live · comparator · “Pemetrexed” · registered Jun 2024
  • NCT04943627 · Agenus Inc. · Phase 3 · comparator · “Pemetrexed” · registered Jun 2021
  • NCT04697628 · Pfizer · Phase 3 · comparator · “pemetrexed” · registered Jan 2021
Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized33 studies
IrinotecanRecent, repeated
Evidence
  • NCT06459180 · Merck & Co., Inc · Phase 3 · live · comparator · “Irinotecan” · registered Jun 2024
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Irinotecan (Camptosar)” · registered Oct 2022
  • NCT04943627 · Agenus Inc. · Phase 3 · comparator · “Irinotecan” · registered Jun 2021
  • NCT04697628 · Pfizer · Phase 3 · comparator · “irinotecan” · registered Jan 2021
Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016)22 studies
FluorouracilRecent, repeated
Evidence
  • NCT07801027 · Merck & Co., Inc · Phase 4 · live · background · “5-Fluorouracil” · registered Aug 2026
  • NCT06535607 · AstraZeneca · Phase 2 · live · background · “5-FU” · registered Jul 2024
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “5-Fluorouracil” · registered Aug 2021
Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed22 studies
Human Papillomavirus Recombinant Vaccine nonavalentRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT05662020 · Beijing Health Guard Biotechnology, Inc · Phase 3 · live · comparator · “GARDASIL® 9” · registered Dec 2022
  • NCT05580341 · Shanghai Zerun Biotechnology Co.,Ltd · Phase 3 · comparator · “GARDASIL ®9” · registered Oct 2022
  • NCT05372016 · Shanghai Bovax Biotechnology Co., Ltd. · Phase 3 · comparator · “Active Comparator: GARDASIL ®9” · registered Dec 2020
Merck & Co., Inc80% of its industry studies22 studies
Interleukin-2Recent, repeatedPhase 4 trial recorded
Evidence
  • NCT06241781 · Grit Biotechnology · Phase 2 · live · background · “IL-2” · registered Jan 2024
  • NCT05357027 · TCRCure Biopharma Ltd. · Phase 2 · background · “IL-2” · registered Jan 2022
Chiron Corporation27% of its industry studies22 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT06505551 · SCG Cell Therapy Pte. Ltd. · Phase 2 · live · background · “Fludarabine” · registered Jul 2024
  • NCT05357027 · TCRCure Biopharma Ltd. · Phase 2 · background · “Fludarabine” · registered Jan 2022
Beijing Biotech18% of its industry studies22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT06505551 · SCG Cell Therapy Pte. Ltd. · Phase 2 · live · background · “Cyclophosphamide” · registered Jul 2024
  • NCT05357027 · TCRCure Biopharma Ltd. · Phase 2 · background · “Cyclophosphamide Capsules” · registered Jan 2022
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies

33 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
volrustomig☆ Track1 live phase-3 study: NCT06079671AstraZeneca
notiretatug rezetecan☆ Track1 live phase-3 study: NCT07418749Jiangsu HengRui Medicine Co., Ltd.
Sutantatug Envedotin☆ Track1 live phase-3 study: NCT07230626CSPC Pharmaceutical Group Limited
adebrelimab☆ Track1 live phase-3 study: NCT07168200Jiangsu HengRui Medicine Co., Ltd.
sacituzumab tirumotecan☆ Track2 live phase-3 studies: NCT07216703, NCT06459180Merck & Co., Inc

The 5 in phase 3 with the nearest primary completion, of 44 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (11)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.izalontamab brengitecan · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 registry mapping onlyNCT05803018 A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies — primary endpoint: Phase Ib: Recommended Phase II Dose (RP2D) · 38 enrolled
  • Dec 2026 est.izalontamab brengitecan · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 main aimNCT05990803 A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies — primary endpoint: Objective response rate (ORR) · 130 enrolled
  • 31 Dec 2026 est.Anti-PD-L1 Antibody-drug Conjugate HLX43 · Fosun Pharma · Phase 2 main aimNCT06769152 A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors — primary endpoint: ORR · 190 enrolled

8 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Uterine Cervical Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 67 open · Antimitotic agents 12 open · Antibody-drug conjugates (ADCs) 9 open · Tyrosine kinase inhibitors (TKIs) 8 open · Antimetabolites 4 open

Coming up

233studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger. 20 (4%) take children under 18. 337 (71%) are for women only and 0 (0%) for men only; 68 (14%) take healthy volunteers.

Recruiting studies that take each age, of 474
AgeWomenMen
1016 (3%)6 (1%)
18382 (81%)128 (27%)
30460 (97%)134 (28%)
40462 (97%)134 (28%)
50443 (93%)133 (28%)
65425 (90%)133 (28%)
75353 (74%)126 (27%)
85269 (57%)110 (23%)

Across all 2,368 studies, recruiting or not: 39% stop at 75 or younger and 23% at 65; 11% take children; 76% are for women only and <1% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Uterine Cervical Neoplasms studies take

Of 204 phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 42 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 147 mo27–68 · 142 studies46 mo29–57 · 84 studies57 mo22–72 · 58 studies
Phase 1/262 mo36–75 · 81 studies62 mo41–75 · 53 studies—
Phase 242 mo29–77 · 204 studies34 mo24–46 · 50 studies46 mo34–88 · 154 studies
Phase 355 mo24–80 · 99 studies34 mo15–55 · 46 studies80 mo48–107 · 53 studies
Phase 457 mo18–86 · 19 studies——
Interventional, no phase33 mo14–71 · 462 studies—32 mo14–71 · 446 studies
Observational58 mo28–158 · 214 studies—59 mo27–158 · 190 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Results posted1

Studies

Recruiting first, then most recently updated. Showing 50 of 2,368. Browse all 2,368 → or search them.